HAVRIX ADULT 1440 HEPATITIS A VACCINE 1440 U.El. / ml injection suspension medication leaflet

J07BC02 hepatitis A vaccine inactivated adsorbed • Antiinfectives for systemic use | Viral vaccines | Hepatitis vaccines

The inactivated adsorbed hepatitis A vaccine is used to prevent infection with the hepatitis A virus (HAV), which can cause acute hepatitis, an inflammatory liver disease. The vaccine contains inactivated hepatitis A viruses adsorbed onto an adjuvant to stimulate a stronger immune response.

The vaccine is administered intramuscularly, usually in two doses, 6-12 months apart. It is recommended for individuals traveling to endemic areas, children, food industry workers, and others at increased risk of infection.

Common side effects include pain at the injection site, mild fever, fatigue, and nausea. In rare cases, severe allergic reactions may occur.

The inactivated adsorbed hepatitis A vaccine is an important preventive measure for reducing the risk of HAV infection and its associated complications, contributing to public health protection.

General data about HAVRIX ADULT 1440 HEPATITIS A VACCINE 1440 U.El. / ml

Substance: hepatitis A vaccine inactivated adsorbed

Date of last drug list: 01-06-2025

Commercial code: W13311002

Concentration: 1440 U.El. / ml

Pharmaceutical form: injection suspension

Packing volume: 1ml

Product type: original

Price: 128.20 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: GLAXOSMITHKLINE BIOLOGICALS SA - BELGIA

Holder: GLAXOSMITHKLINE BIOLOGICALS S.A. - BELGIA

Number: 441/2007/02

Shelf life: 3 years

Pharmaceutical forms available for hepatitis A vaccine inactivated adsorbed

Concentrations available for hepatitis A vaccine inactivated adsorbed

1440 U.El./ml, 160U, 720 U.EI./0.5ml, 80U/0.5ml

Other substances similar to hepatitis A vaccine inactivated adsorbed